Association of serum lipoprotein ratios with insulin resistance in type 2 diabetes mellitus

Indian Journal of Medical Research

Volumn 131, Issue 5, 2010, Pages 641-648

  Tangvarasittichai, Surapon ^a   Poonsub, Prapaporn ^b   Tangvarasittichai, Orathai ^a  

^a NARESUAN UNIVERSITY   (Thailand)

^b BUDDHACHINARAJ HOSPITAL   (Thailand)

Author keywords

HOMA IR; Insulin level; Serum lipoprotein ratios; Type 2 diabetes mellitus

Indexed keywords

CHOLESTEROL; GEMFIBROZIL; GLIBENCLAMIDE; GLIPIZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; INSULIN; LIPID; LIPOPROTEIN; METFORMIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY HEALTH CARE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; WAIST CIRCUMFERENCE;

AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS; MALE; MIDDLE AGED;

EID: 77952357646     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Meigs JB. Epidemiology of the metabolic syndrome. Am J Manag Care 2002; 8 (11 Suppl): S283-92; quiz S293-6.
2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
3. Assmann G, Schulte H. The Prospective Cardiovascular Münster (PROCAM) study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Amer Heart J 1988; 116: 1713-24.
4. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
5. Syvänne M, Taskinen M-R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997; 350 (S1): S20-3.
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
7. Garg A, Grundy SM Management of dyslipidemia in NIDDM. Diabetes Care 1990; 13: 153-69.
8. Sheu WH, Shieh SM, Fuh MM, Shen DD, Jeng CY, Chen YD, et al. Insulin resistance, glucose intolerance, and hyperinsulinemia. Hypertriglyceridemia versus hypercholesterolemia. Arterioscler Thromb Vasc Biol 1993; 13: 367-70.
9. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 1992; 231: 25-30.
10. Reavan GM. Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease: syndrome X revisited. In: Jefferson LS, Cherrington AD, editors. Handbook of physiology: Section 7: The endocrine system. Vol. II: The endocrine pancreas and regulation of metabolism. New York: Oxford University Press; 2001. p. 1169-97.
11. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1: 16-9.
12. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9.
13. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373-81.
14. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) Trial. Circulation 2000; 102: 1886-92.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
16. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-93.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
18. Feeman WE, Jr, Niebauer J. Prediction of angiographic stabilization/regression of coronary atherosclerosis by a risk factor graph. J Cardiovasc Risk 2000; 7: 415-23.
19. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996; 19: 1138-41.
20. Wilson PW, Kannel WB, Anderson KM. Lipids, glucose intolerance and vascular disease: the Framingham Study. Monogr Atheroscler 1985; 13: 1-11.
21. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 1992; 231: 25-30.
22. Morar N, Seedat YK, Naidoo DP, Desai DK. Ambulatory blood pressure and risk factors for coronary heart disease in black and Indian medical students. J Cardiovasc Risk 1998; 5: 313-8.
23. Jeppesen J, Facchini FS, Reaven GM. Individuals with high total cholesterol/ HDL cholesterol ratios are insulin resistant. J Intern Med 1998; 243: 293-8.
24. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987; 114: 413-9.
25. Castelli WP. Cardiovascular disease in women. Am J Obstet Gynecol 1988; 158: 1553-60.
26. Li C, Ford ES, Meng YX, Mokdad AH, Reaven GM. Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity? Cardiovasc Diabetol 2008; 7: 4.
27. McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005; 96: 399-404.
28. Syvanne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997; 350 (Suppl 1): SI20-3.
29. Fagan TC, Deedwania PC. The cardiovascular dysmetabolic syndrome. Am J Med 1998; 105: 77S-82S.
30. Sheu WH, Jeng CY, young MS, Le WJ, Chen YT. Coronary artery disease risk predicted by insulin resistance, plasma lipids, and hypertension in people without diabetes. Am J Med Sci 2000; 319: 84-8.
31. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-49.
32. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, yki-Jarvinen H, et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997; 40: 454-62.
33. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. Curr Opin Lipidol 2006; 17: 238-46.